Phil Taylor

BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside China.

A new programme announced by the FDA will work towards the use of augmented reality and virtual reality (AR/VR) to make patients' own homes an integral part of the healthcare system.

An oral therapy that can allow children and adolescents with an aggressive form of brain cancer to be treated at home rather than in hospital has been recommended for use by the NHS in England and Wales.

Any new company wanting to make waves in applying artificial intelligence to drug discovery will need deep pockets and a top-tier science and

Roche chief executive Thomas Schinecker said today that one in five of the pharma division's pipeline of new molecular entities (NMEs) has been culled in the last few months as part of a shift in focus on “high impact” projects.

Biogen says sales of Eisai-partnered Alzheimer’s therapy Leqembi are building, though it remains slow going

Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fibrosis and solid tumours.

PDC Classics airs on Sky Sports Arena HD at 3:45 AM, Friday 26 April. (Subtitles.)

Highlights of Matthew Sweet along with special guest Abe Partridge at Hendricks Live performing arts center in Plainfield.

Highlights of Matthew Sweet along with special guest Abe Partridge at Hendricks Live performing arts center in Plainfield, April,24 2024 in Plainfield, Indiana. Mandatory photo credit: Phil Taylor/ Nuvo Photographer